RA0121

antibody from Oursmab

Targeting: CD47 IAP, MER6, OA3

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0121

Provider

Oursmab

Product name

Ligufalimab (Biosimilar Reference Antibody) (CD47)

Antibody type

Monoclonal

Description

Ligufalimab (also known as AK117) is a humanized IgG4 monoclonal antibody that specifically targets CD47, a cell-surface protein known as a ¡°don¡¯t eat me¡± signal. Its IgG4 isotype is selected to minimize effector functions like antibody-dependent cellular cytotoxicity (ADCC). A key distinguishing feature of ligufalimab is its engineered binding property that does not induce red blood cell (RBC) agglutination, a common side effect associated with anti-CD47 antibodies. By blocking the interaction between CD47 and its macrophage receptor SIRP¦Á, it selectively promotes the phagocytosis of tumor cells by macrophages. It is under clinical investigation for the treatment of advanced solid tumors and hematologic malignancies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.